Author: Alina Brinza (Moldova, Republic of)
Co-authors: Natalia Corduneanu, Maria Iacubitchi, Angela Corduneanu
Purpose
To describe a clinical case of a young woman with diagnosis of proliferative vascular retinopathy and Dermatomyositis.
Setting/Venue
Clinical Republic Hospital ”Timofei Mosneaga”, Chisinau, Moldova. State University of Medicine and Pharmacy of Moldova ”Nicolae Testemitanu”, Chisinau, Moldova. Medclinic International, Chisinau, Moldova.
Methods
Review of a five years follow-up of a patient with diagnosis of bilateral vascular proliferative retinopathy and Dermatomyositis with esophageal involvement. Ophthalmoscopic findings, Fluorescein Angiography (FAG), Color fundus photography, and responses to treatments were evaluated.
Results
A 27 years female patient was referred to our clinic for a regular eye examination, 5 months after the onset of dermatomyositis. On examination, visual acuity Right eye 1.0, Left eye 1.0. Anterior segment within normal limits. Funduscopy showed, microhaemorrages and a lot of retinal neovessels in both eyes. The established diagnosis was proliferative vascular retinopathy in dermatomyositis. The patient received treatment with multiple intravitreal anti-VEGF injections, she opted for Bevacizumab. Despite the good response to the treatment of dermatomyositis with methylprednisolone 4 mg per day and metotrexate 15 mg per week, the retinal neovascularisation reactivates within 3-4 months after anti-VEGF injections. FAG revealed hyperfluorescent areas that increase in size and intensity in the later phases of the test. After two years of intravitreal injection, visual acuity of left eye was reduced to 0.8 and of right eye to 0.9, due to posterior subcapsular cataract. The laser retinal photocoagulation has been performed, and the follow-up of the case continues.
Conlusions
Proliferative vascular retinopathy may occur secondary to Dermatomyositis. It is very important that all clinicians must be aware of this rare association, in order to detect and treat in its early stage.
Financial Disclosure
No
Comments
-